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Abstract: Although paracetamol is recommended as first line pharmacological therapy for mild to moderate 
osteoarthritis (OA) of the knees, it is deemed to be not as efficacious as other pharmacological agents. One of the 
reasons could be due to poor adherence and persistence to therapy. This study examines the efficacy of the early 
response and the response after four weeks to paracetamol in mild to moderate OA of the knees in daily clinical 
practice. This is an open label study. Consecutive patients with mild to moderate OA of the knees were given 1.3 
grams extended-release paracetamol three times per day for 4 weeks. Pain based on the Western Ontario and 
McMaster Universities (WOMAC) v3 VAS osteoathritis index was used as a measure of efficacy. Serial liver and 
renal profiles were done for safety monitoring. An early assessment of efficacy was done at week 1 and a later at the 
end of 4 weeks of therapy. The primary efficacy endpoint was a 30% reduction in global pain score at week 4 
compared to baseline Analysis was done using the SPSS Version 18. Thirty patients entered the study. 73.3% were 
females. Mean age, BMI and duration of OA was 58.5years (SD±6.9), 28.1 kg/m2 (SD±6.4) 22.8 (SD±32.2) months 
respectively.  The mean VAS WOMAC at baseline for pain was 35.4mm (SD±17.5). At the end of the first week of 
therapy, there was no difference in the WOMAC pain score compared to baseline. (95% CI -0.54-12.1, p=0.07). 
However by the end of 4 weeks there was a statistically significant 46.6% (95% CI 27.6-72.6, p<0.001) reduction in 
global pain compared to baseline. An absolute reduction of 16.5mm in global pain (95% CI 9.9-23.0, p<0.001) 
compared to baseline was also seen. No serious adverse events were encountered. Paracetamol used to treat OA of 
the knees is not efficacious in the first week of therapy. However persistence with therapy for a further three weeks 
results in significant reduction in pain. Therefore every effort should be made to ensure persistence with the 
recommended full four weeks of treatment.  
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1. Introduction 
 Osteoarthritis (OA) of the knees is a 
common disorder  amongst older individuals in the 
community.1-2  Many present to primary care doctors 
with complaints of pain.1-2 and are often prescribed 
non-steroidal anti-inflammatory agents (NSAIDs) or 
cyclo-oxygenase2 inhibitors (COX-2).2   While these 
agents are efficacious, they are associated with 
serious adverse events especially when used for 
longer duration in conditions like OA of the knees.3-4  
Elderly patients tend to have more comorbidities and 
therefore require multiple medications. Therefore, 
drug interactions are more likely to occur in this 
group of patients.5 
Recent studies have reported that the use of 
NSAIDs and COX-2 inhibitors is associated with 
increased cardiovascular events.4-6  Furthermore, 
although paracetamol is recommended as first line 
treatment by various guidelines for the management 
of OA of the knees, it is often under-prescribed. 7-8   
 Various reasons have been cited as to why 
paracetamol is not efficacious.9-11  One of the reasons 
could be the poor adherence.12  Regular paracetamol 
has to be taken four times a day and it is well known 
that frequent medication dosing is inversely related to 
adherence to therapy.13-14  Furthermore, patients 
frequently do not persist with the recommended 4 
weeks therapy as they tend to give up when they do 
not appreciate any significant reduction in pain 
within the first few days of taking medication, rather 
than persisting longer with the therapy. 
  A literature search produced very few 
studies that looked at the effect of paracetamol after 
the first week of therapy in the treatment of OA 
knees compared to the effects seen later with 
persistence of therapy. Two studies study examined 
efficacy of paracetamol compared to placebo at one 
week 15-16  but these studies were not extended 
beyond one week and thus do not allow comparisons 
with prolonged use.  One other study did look at the 
efficacy of paracetamol compared to placebo at one 
week and six weeks but unfortunately did not report 
on paracetamol at week one and at week six 
compared to baseline.17    
 Yet another study compared efficacy of 
paracetamol at 2 weeks and 12 weeks and found no 
significant reduction in pain compared to baseline at 
any of these two time intervals.18 Of note is that all 
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these studies used regular paracetamol that requires 
four times a day dosing. 
 We thus examined the early response and 
compared it to the response after 4 weeks of 
extended-release paracetamol in treating mild to 
moderate OA of the knees. 
 
2. Matetrials and Methods  
 We conducted an open label study using 
extended-release paracetamol amongst patients 
presenting with osteoarthritis of the knees at a 
university based primary care clinic. The reason for 
using an open label study was to emulate a real life 
clinical practice scenario. Furthermore, a placebo 
controlled trial would be deemed to be unethical in 
the light of available and efficacious therapy for OA 
knees, especially as the patients who present to our 
clinic which is located in a tertiary teaching hospital 
are usually patients who either have more severe or 
of longer duration illnesses and would have had 
received previous treatment by other primary care 
doctors without much improvement. An extended-
release formulation was chosen as it needs to be 
taken only three times daily and this in itself may 
enhance adherence. 
 Consecutive patients with mild to moderate 
unilateral or bilateral OA of the knees based on the 
American College of Rheumatology diagnostic 
criteria19   were eligible for the study. 
 Those with inflammatory arthritis, 
contraindication to use of paracetamol, chronic liver 
disease, trauma, surgery or corticosteroid injection of 
knee within past 3 months, psychiatric illness, 
pregnancy, inability to walk unassisted or with knee 
effusion were excluded from the study. 
 This was a 4-week active treatment study in 
concordance with the recommendations of 
rheumatology societies of treatment with paracetamol 
for 4 weeks in mild to moderate OA knees.19-21 
However neither the guidelines nor the clinical trials 
for OA knees have assessed efficacy in the early 
stages of treatment. As we wanted to compare 
efficacy at early to late stage of therapy, we evaluated 
the patients at baseline, at the end of one week of 
therapy and at a final visit in week 4. 
 Also because of the concern of safety of 
prolonged use at full dose of paracetamol in the 
background of a high prevalence of Hepatitis B 
carrier in the country, liver and renal biochemistries 
were done after one week for safety monitoring and 
again at the end of 4 weeks of therapy. For those with 
biochemistry abnormalities, further follow-up was 
done one month after the active treatment had ended. 
 Demographic data and physical examination 
were done at baseline. The Western Ontario and 
McMaster Universities WOMAC22 v3 VAS 
osteoarthritis index from 0-100 mm was applied at 
baseline, week 1 and week 4 for pain, function and 
stiffness. 
 Weight loss was emphasised to all 
overweight and obese patients. All patients were also 
taught knee exercise by the trained research assistant. 
This was provided as part of the care recommended 
by the various guidelines. 
 All patients were prescribed 1.3 Grams of 
extended-release paracetamol (Panadol ExtendTM ) 
three times daily for 4 weeks. Efficacy of treatment 
was assessed by change in the WOMAC pain score at 
week 1 and week 4 compared to baseline. 
 The primary end point chosen was a 30% 
decrease in global pain intensity between baseline 
and week 4 in accordance to recommendations of a 
report by the Osteoarthritis Research Society 
International (OARSI).23 .The secondary efficacy end 
point was a reduction of 10mm on the WOMAC pain 
score between baseline and week 1, week 1 and week 
4 and baseline and week 4. This is the consensus 
level of response for efficacy studies of OA knees.23 
Based on a power of 80% and a two-sided α value of 
5%, and a defaulter rate of 20%, the number of 
patients needed is 30. 
 Compliance was measured by a daily diary 
and pill count. 
 Analysis was done using SPSS version18 
and was done on an intention to treat analysis.   
Written informed consent was obtained from all 
patients and approval for the study was granted by 
the institution’s University of Malaya Medical Centre 
Ethics Subcommittee. 
 
3. Results 
  A total of 30 patients entered the study and 
25 (83.3%) completed the study. Four patients 
attended the week 1 visit, said they felt better and did 
not want to continue with the study. One had 
diarrhoea and voluntarily withdrew from the study at 
week 1, although the investigators deemed that she 
could continue with the study. In the 25 patients who 
completed the study, both at week 1 and week 4, less 
than 4% of each outcome variable of the pain 
WOMAC v3 VAS score was missing. 
 Table 1 shows the baseline characteristics of 
the study patients.  Majority of the patients were 
females and two thirds were overweight or obese. 
Bilateral OA was common too seen in nearly three 
quarters of the patients. 
The results presented here are the intention 
to treat analysis. There was no difference in the 
intention to treat and per protocol analysis on the 
primary outcome and liver toxicity.  
Table 2 shows the percentage change and 
Table 3 the absolute change in global WOMAC 
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Score in pain, stiffness and difficulty in function at 
week 1 and week 4 compared to baseline. 
 
Efficacy of early and late response to paracetamol  
 Although an early reduction in pain of 
5.8mm was seen after one week of therapy, this was 
not statistically significant (95% CI -0.54-12.1, 
p=0.07).  Furthermore the magnitude of pain 
reduction did not meet the primary efficacy end point 
either. 
However at the end of 4 weeks of treatment, 
the reduction in pain was nearly 50% (CI 27.6-72.6, 
p<0.001) when compared to baseline.  There was also 
a statistically significant reduction of 16.5mm (95% 
CI 9.9-23.0, p<0.001) on the WOMAC pain score at 
the end of 4 weeks compared to baseline.  
Furthermore the reduction in WOMAC pain 
score of 10.7mm was also significant between week 1 
and week 4 (95% CI 2.8-18.6, p=0.01). 
A reduction in stiffness of nearly 30% and in 
difficulty in function of 34.9% was also seen between 
week 4 and baseline. There was also a statistically 
significant reduction of 12.3mm and 15.2mm in 
stiffness and difficulty in function respectively at the 
end of the study when compared to baseline. 
 
Table 1: Baseline Characteristics of Study Patients 
(N=30) 
Variable Mean  ±SD 
Age (years) 58.5  (6.9) 
BMI kg/m2 28.1 (6.4) 
Duration of OA (months) 22.8 (32.2) 
 
Variable N (%) 
Females 22 (73.3%) 
Overweight and Obese  
(BMI ≥25 kg/m2) 
19 (63.3%) 
Obesity (BMI ≥30 kg/m2)  8 (26.7%) 
Bilateral OA 21 (70%) 
 
 
Table 2: Percentage Reduction in WOMAC Score in pain, stiffness and difficulty in function at week 1 and week 4 
compared to baseline 
 %  change in WOMAC VAS (95% CI) 
 Wk0-Wk1 p Wk1-W4 p Wk0-Wk4 p 
Pain 
16.4 
 (-2.4-43.3) 
0.071 35.8  
(1.9-59.2) 
0.001 46.6  
(27.6-72.6)  
<0.001 
Stiffness 
6.8  
(-13.9-30.0) 
0.47 23.7  
(-12.8-41.2) 
0.09 28.9  
(15.0-53.4) 
0.03 
Difficulty in 
Function 
18.2  
(1.5-37.7)  
0.02 20.5  
(-2.6-49.5) 
0.06 34.9  
(20.5-62.5) 
<0.001 
 
 
 
 
Global WOMAC Score (0-100 mm VAS) 
Mean Score (mm) Absolute Reduction in mm  
( 95% CI), (p value) 
 
Wk 0 Wk 1 Wk 4 Wk 0-1 Wk 1-4 Wk 0-4 
Pain 35.4 29.6 18.9 
5.8 
(-0.54-12.1) 
(p=0.07) 
10.7 
(2.8-18.6) 
(p=0.01) 
16.5 
(9.9-23.0) 
(p<0.001) 
Stiffness 42.5 39.6 30.2 
2.9 
(-6.5-12.2) 
(p=0.48) 
9.4 
(-1.8-20.6) 
(p=0.09) 
12.3 
(2.2-20.6) 
(p=0.03) 
Difficulty in 
Function 
43.5 35.6 28.3 
7.9 
(1.3-15.1) 
(p=0.02) 
7.3 
(-0.3-14.4) 
(p=0.06) 
15.2 
(7.3-23.2 ) 
(p<0.001) 
 
 
  
Table 3: Absolute Change in WOMAC pain, stiffness and difficulty in function score at baseline, week 1 and week 4 
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Safety and Tolerability 
There were no serious adverse events 
encountered.  Minor adverse events included 
dizziness (two) and diarrhoea (one).  
There were also no clinically significant 
changes in the liver enzymes. Although there was 
some elevation in liver enzymes seen between 
baseline and at the end of week 4, none of it was 
raised more than twice the upper limit of normal. For 
those with raised liver enzymes, a follow-up was 
done a month after the study ended and repeat blood 
tests showed their enzymes had reverted to their 
baseline.  There were also no significant changes in 
renal function. 
Compliance was very good with all the 25 
completers achieving a compliance of between 96-
98% at week 1 and 94- 96% at week 4 based on the 
patient’s daily diary and pill count.  In four of the 
defaulters, the compliance was between 80-86% at 
week 1, after which they did not wish to continue 
with the study as they said they felt their pain was 
very much reduced. The defaulter who had diarrhea 
took the medication for 3 days only and voluntarily 
withdrew from the study when reviewed at week 1 
 
4. Discussions  
Paracetamol is recommended as first line 
pharmacotherapy by various guidelines on the 
management of OA of the knees.19-21  This study, 
done to reflect daily clinical practice, shows that with 
persistence, extended-release paracetamol  given at a 
dose of 1.3 gram three times daily for four weeks is 
effective in reducing pain in patients with mild to 
moderate OA of the knees. It is also effective in 
reducing stiffness and in improving function and is 
safe and well tolerated. This safety and tolerability 
has since been confirmed in other studies when 
paracetamol was given for six weeks or longer.17, 24   
 Our study does not have a placebo or 
control arm for comparison and it can be argued that 
paracetamol may be no better than a placebo.18  
While it is acknowledged that the lack of a placebo or 
control arm is one of the limitations of our study, 
several randomized control trials have shown greater 
efficacy of paracetamol compared to placebo.15-16,25  
However, a meta-analysis26   has shown that it is less 
efficacious than NSAIDs26 providing greater support 
for the use of NSAIDs instead of paracetamol for OA 
of the knees. But many of the studies which show 
NSAIDs to be more effective than acetaminophen26-28  
were usually done in patients with more severe pain 
and longer duration of symptoms.26-28  On the other 
hand, several studies have shown that there is no 
difference when acetaminophen, either regular or the 
extended formulation is compared against an 
NSAID.29-30  Furthermore, the effect size seen in 
NSAIDs versus placebo studies is only 0.34, (95% CI 
0.14-0.54) and this is not much greater than the effect 
size of paracetamol versus placebo26   (effect size 
0.21,  95% CI 0.02-0.41).  Hence, based on our study 
which was done in a primary care setting and 
emulating daily clinical practice, there is still a case 
for using paracetmaol as first line pharmacotherapy 
especially in mild to moderate OA of the knees. 
Most of the above mentioned studies 
compared therapies at the end of 4 weeks or longer.17-
18, 24-25, 27-29 Very few have been done to compare the 
effect of short term therapy.15-16 Even fewer 
compared early response to response with persistent 
drug usage. A randomized short term study of one 
week15 found significant reduction in pain with 
paracetamol over placebo. But another randomized 
short term study, also of one week, found that while 
paracetamol was superior to placebo, NSAIDS was 
superior to paracetamol.16   Unfortunately these two 
studies were only for a week and thus it was not 
possible to examine the efficacy with longer use. A 
possible outcome, if there was a comparison of 
longer use, could be a narrowing of the differences in 
efficacy between NSAIDs and paracetamol. One 
study did examine the efficacy of paracetamol at 2 
weeks and 12 weeks compared to baseline but found 
no difference in efficacy with prolonged use.18 In this 
same study the reduction in pain was significant and 
seen early at 2 weeks with the use of diclofenac, 
suggesting an earlier onset of pain relief with 
NSAIDs compared with paracetamol. Because there 
were very few studies that compared early response 
to response after four weeks of paracetamol use, our 
study aimed to do this. Our results did show that 
there is significant benefit with persistent use, unlike 
that of one study18 that showed that there was no 
significant response at 2 nor at 12 weeks compared to 
baseline. 
Our study also shows that while there was 
some early reduction in pain and stiffness, this was 
not statistically significant. This finding does not 
suggest that there is no effect but that the lack of 
statistical significance could have been due to the 
small number of patients. However with persistent 
use of paracetamol, the improvement became greater 
and significant. While we studied the response after 
one week of therapy, this time point was an arbitrary 
choice. We decided to see the patient earlier rather 
than at the end of 4 weeks as recommended by 
guidelines was because we were concerned about the 
safety of full dosing for four weeks. This was 
because at the time of our study there was no 
available data about safety of paracetamol of longer 
than 2 weeks duration of use. While our study 
showed a statistically significant reduction in pain at 
the end of 4 weeks but not after one week, the 
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response at the end of 2 weeks or even at the end of 
three weeks remain unknown. In fact  a meta-analysis 
of short term efficacy of pharmacotherapeutic 
interventions concluded that there was not enough 
data to identify a time point for maximum effect of 
paracetamol within a 4 week time frame for treatment 
of OA knees.31 This being the case, our study helps to 
support the recommendation of using paracetamol for 
a full four weeks. 
A limitation of our study was that it was 
conducted for four weeks only and efficacy for a 
longer duration of therapy was not evaluated. 
However our purpose was to emulate daily clinical 
practice. To be in accordance with the OA guidelines 
recommendations, patients are to be reviewed after 
four weeks of paracetamol therapy and a decision 
made then on further management at this time point 
depending on the response of the patients. Hence we 
did not proceed beyond the 4 weeks. It is likely that a 
longer study may show a continued persistence but 
not necessarily a further improvement in the benefit.  
In fact one study which compared paracetamol 
against placebo did not show any significant 
improvement at 2 weeks compared to baseline and it 
also did not show any further improvement at 12 
weeks compared to baseline.18. This suggests that no 
further improvement can be seen after the maximum 
efficacy seen at four weeks is already attained.  
It has to be acknowledged that the response 
seen in our study could have been a result of a 
regression to the mean or to a response shift. 32-33 
However, the mean duration of OA symptoms of our 
study patients was nearly 2 years and not new onset 
OA, and it is unlikely that a regression to the mean or 
a response shift alone could have accounted for the 
response seen.  
 Another confounding factor would be that 
the reduction in pain seen in our patients could have 
been due to the knee exercise given to all of them. 
While this may be the case, we wanted to emulate 
best clinical practice and to be in accordance with 
guideline recommendations of combining non-
pharmacological with pharmacological therapy. 
Hence we proceeded to provide knee exercise. We 
acknowledge that the presence of a control arm of 
exercise but without paracetamol, may have helped to 
eliminate this confounding issue. But again as these 
are not patients with newly diagnosed OA, it is 
unlikely that knee exercise alone would have 
accounted for the response seen. As such, inspite of 
all the above limitations there is still a sound reason 
to use paracetamol as first line as recommended by 
the various guidelines.  
Our finding thus has implications as it adds 
to the dearth of data supporting persistence with 
paracetamol use. Our finding also suggests that it is 
important to remember that patients should persist 
and stay on treatment with paracetamol for longer, 
and that doctors should resist the pressure to change 
to another medication too soon.34-35 
Effectiveness of paracetamol is related to 
adequate dosage. Doctors and other health care 
providers often do not use paracetamol adequately 
and thus paracetamol is perceived by doctors as well 
as patients not to be effective7,9 Furthermore, 
compliance to a four times daily dosing is usually 
poorer than a less frequent daily dosing. Compliance 
to a three times a day extended preparation is 
excellent here. While our study shows that the 
treatment of OA of the knees with paracetamol is 
significantly efficacious, several other studies failed 
to show this.17-18One of the reasons for this difference 
could be the better compliance with an extended 
preparation seen in our study as for example versus 
72% seen in another study17. Furthermore, many of 
the other studies used the regular four times a day 
dosing paracetamol and the studies were of a longer 
duration.17-18These factors could have contributed to 
the poorer compliance12-13 and hence may have 
contributed to their lack of positive findings. 
Although it is recognized that patients in studies tend 
to be more compliant because of close supervision, 
doctors, nevertheless, should try to prescribe 
extended preparations in full doses as far as possible 
12-13 and patients should be encouraged to take 
medication regularly according to the directions to 
reduce pain episodes.34-35 
Given that more adverse events are 
associated with NSAIDs use3-4 and that patients 
would forgo some degree of effectiveness for safety36 
NSAIDS are thus not necessarily superior to 
paracetamol, especially in patients presenting to a 
primary care clinic with mild to moderate OA knees. 
Together with the excellent safety and tolerability of 
using paracetamol in full dose for 4 weeks and its 
good safety/benefit ratio, there is still a case for 
advocating the use of paracetamol as first line 
therapy in OA of the knees. 
The aim of management of OA is not to cure 
as this is not realistically possible, but to relieve pain, 
improve function and improve quality of life. This 
study has shown a reduction in pain severity and this 
is achieved with minimal adverse events with 1.3 
grams of extended release paracetamol given three 
times daily and persisted for a full four weeks.   
 
5. Conclusion 
 Paracetamol used to treat OA of the knees is 
not efficacious in the first week of therapy. However 
persistence with therapy for a further three weeks 
results in significant reduction in pain. Therefore 
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every effort should be made to ensure persistence 
with the recommended full four weeks of treatment. 
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